Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Dolph

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Pharmacoeconomics|August 9, 2021
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON TrialMichael Dolph, Gabriel Tremblay, Hoyee Leong
Journal of Health Economics and Outcomes Research|October 7, 2021
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple MyelomaMichael Dolph, Gabriel Tremblay, Adrienne M Gilligan, et al.
Psychiatry Research|July 9, 2015
A randomised trial of nutrient supplements to minimise psychological stress after a natural disasterBonnie J Kaplan, Julia J Rucklidge, Amy R Romijn, et al.
ISRN Urology|September 13, 2013
ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate CancerLiang Hong Teng, Cheng Wang, Michael Dolph, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2012
ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortalityTarek A Bismar, Michael Dolph, Liang-Hong Teng, et al.
Journal of Hematology & Oncology|March 11, 2014
Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosisSamir Al Bashir, Mohammed Alshalalfa, Samar A Hegazy, et al.
Future Oncology (London, England)|November 29, 2024
Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparisonFaiz Anwer, Tommy Lan, Michael Dolph, et al.
Cancer Biology & Therapy|June 28, 2014
The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapyKuo-Cheng Huang, Mohammed Alshalalfa, Samar A Hegazy, et al.
Urology|June 11, 2013
ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized diseaseLiang-Hong Teng, Cheng Wang, Louis R Bégin, et al.
Cancer Medicine|January 10, 2014
The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targetingBin Xu, Liang Hong Teng, Sabrina Daniela da Silva, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Pharmacoeconomics|August 9, 2021
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON TrialMichael Dolph, Gabriel Tremblay, Hoyee Leong
Journal of Health Economics and Outcomes Research|October 7, 2021
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple MyelomaMichael Dolph, Gabriel Tremblay, Adrienne M Gilligan, et al.
Psychiatry Research|July 9, 2015
A randomised trial of nutrient supplements to minimise psychological stress after a natural disasterBonnie J Kaplan, Julia J Rucklidge, Amy R Romijn, et al.
ISRN Urology|September 13, 2013
ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate CancerLiang Hong Teng, Cheng Wang, Michael Dolph, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2012
ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortalityTarek A Bismar, Michael Dolph, Liang-Hong Teng, et al.
Journal of Hematology & Oncology|March 11, 2014
Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosisSamir Al Bashir, Mohammed Alshalalfa, Samar A Hegazy, et al.
Future Oncology (London, England)|November 29, 2024
Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparisonFaiz Anwer, Tommy Lan, Michael Dolph, et al.
Cancer Biology & Therapy|June 28, 2014
The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapyKuo-Cheng Huang, Mohammed Alshalalfa, Samar A Hegazy, et al.
Urology|June 11, 2013
ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized diseaseLiang-Hong Teng, Cheng Wang, Louis R Bégin, et al.
Cancer Medicine|January 10, 2014
The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targetingBin Xu, Liang Hong Teng, Sabrina Daniela da Silva, et al.
Pageof 2